Two major things that were milestones for us; we’re launching a product called Sofia. We’re also launching the AmpliVue C. difficile product. Both of those should be responsible for pretty good lift 2013 longer terms in terms of our goals, we’ve stated publicly before that by 2015 we expect to be around $250 million in revenues. That’s about $100 million more than we have today. Big drivers to that of course are the Sofia platform as well as the molecular platform.

Isaac Ro - Goldman Sachs

And maybe just start with Sofia and give us a little more depth as to the customer, what your experience will look like, how do you compare that competitively against some of the other offerings in the marketplace?

Doug Bryant

Today, here in the United States we’ve launched just Sofia with the flu product and so my comparison competitively is only there I can say that we knew that we had something as we were developing and this assay is actually about 100% more sensitive than our legacy products. So we knew that we would see during the clinical trials better performance for both sensitivity to flu A and flu B. We didn’t realize how well it would compare with PCR.

Read the rest of this transcript for free on seekingalpha.com

If you liked this article you might like

Abbott CEO: Another Alere-Related Divestiture Coming Soon

Alere, St. Jude Deals in Focus as Abbott Releases Q2 Earnings

Quidel Diversifies With Alere's Triage Assets

Action Was Under the Surface in Monday's Market

Insider Trading Alert - QDEL, SPRT And SJW Traded By Insiders